Page 391«..1020..389390391392

CSC news links 2010-04-18

By Dr. Matthew Watson

For links to recent news items, visit these [Twitter] or [FriendFeed] pages. Examples of a few news items that have received attention:

To Read More: CSC news links 2010-04-18
categoriaStem Cell Therapy commentoComments Off on CSC news links 2010-04-18 | dataApril 19th, 2010
Read All

Stimulating Biotechnology: Maryland has embarrassment of riches and challenges – WTOP

By Dr. Matthew Watson


Frederick News Post (subscription)
Stimulating Biotechnology: Maryland has embarrassment of riches and challenges
WTOP
When it comes to biotechnology, Maryland is perhaps the most gifted underprivileged state in the country. And the federal economic stimulus package may be ...
Stimulating biotechnology: Signs of recovery apparent in challenging environmentFrederick News Post (subscription)

all 3 news articles »

To Read More: Stimulating Biotechnology: Maryland has embarrassment of riches and challenges – WTOP
categoriaUncategorized commentoComments Off on Stimulating Biotechnology: Maryland has embarrassment of riches and challenges – WTOP | dataApril 18th, 2010
Read All

Sen. Robert Menendez named Legislator of the Year by bio-technology organization – The Jersey Journal – NJ.com

By Dr. Matthew Watson


The Jersey Journal - NJ.com
Sen. Robert Menendez named Legislator of the Year by bio-technology organization
The Jersey Journal - NJ.com
Robert Menendez, D-Hoboken, was named yesterday as Legislator of the Year by BIO, an umbrella organization " representing 1200 biotechnology companies, ...
Senator Menendez Honored As BIO Legislator Of The YearMedical News Today (press release)
Representative Eshoo Honored as BIO Legislator of the YearSYS-CON Media (press release)

all 4 news articles »

To Read More: Sen. Robert Menendez named Legislator of the Year by bio-technology organization – The Jersey Journal – NJ.com
categoriaUncategorized commentoComments Off on Sen. Robert Menendez named Legislator of the Year by bio-technology organization – The Jersey Journal – NJ.com | dataApril 18th, 2010
Read All

One Embryo Plus Three Parents Equals Ethical Dilemma – Care2.com (blog)

By Dr. Matthew Watson


ABC Online
One Embryo Plus Three Parents Equals Ethical Dilemma
Care2.com (blog)
It is a form of genetic engineering, a subject long on controversy and rife with ethical dilemma. Scientists at Newcastle University have developed a ...
3-Parent Embryos Could Prevent Disease, But Raise Ethical IssuesWired News
British Scientists Create Three-Parent EmbryosChristianityToday.com (blog)
UK Scientists Clone 3-Parent EmbryosFamily Research Council (blog)
FOXNews
all 239 news articles »

To Read More: One Embryo Plus Three Parents Equals Ethical Dilemma – Care2.com (blog)
categoriaUncategorized commentoComments Off on One Embryo Plus Three Parents Equals Ethical Dilemma – Care2.com (blog) | dataApril 17th, 2010
Read All

MicroRNA therapy could be a powerful tool to correct the CSC dysregulation?

By Dr. Matthew Watson

Medical Hypothesis: No small matter: microRNAs - key regulators of cancer stem cells by Qing Ji, David Karnak, Ping Hao, Rongquan Wang and Liang Xu, Int J Clin Exp Med 2010(Mar 12); 3(1): 84-7 [FriendFeed entry][Full text via PMC]. PubMed Abstract:

Emerging evidence demonstrates that both tumor suppressor and oncogenic miRNAs play an essential role in stem cell self-renewal and differentiation by negatively regulating the expression of certain key genes in stem cells. It seems logical that they may also be critical players in cancer stem cells. Though small in size, miRNAs play a key role in the epigenetic regulation of cancer stem cells. Specifically, the imbalance of oncogenic vs. tumor suppressor miRNAs may lead to dysregulation of cancer stem cells, thus causing excessive self-renewal and survival of cancer stem cells, and resistance to chemo/radiotherapy. We postulate that restoring the balance of miRNAs will correct this dysregulation via the direct and simultaneous modulation of downstream stem cell pathways involved in cancer stem cell self-renewal and/or differentiation. The resultant restoration of key regulatory pathways could improve therapeutic response. Restoring tumor suppressor miRNAs and/or inhibiting oncogenic miRNAs may provide a novel molecular therapy for human cancers, potentially via modulating cancer stem cells.

To Read More: MicroRNA therapy could be a powerful tool to correct the CSC dysregulation?
categoriaStem Cell Therapy commentoComments Off on MicroRNA therapy could be a powerful tool to correct the CSC dysregulation? | dataApril 17th, 2010
Read All

Venture Capital Investing Climbs to $4.73 Billion (Correct) – BusinessWeek

By Dr. Matthew Watson


TopNews United States
Venture Capital Investing Climbs to $4.73 Billion (Correct)
BusinessWeek
The biggest declines came in software and biotechnology, the association said. The number of software deals was the lowest in any quarter since 1995, ...
Dallas-area venture capital investments slip in quarterDallas Morning News
MoneyTree: Venture investing remains weak in Phila. area and nationPhiladelphia Business Journal
Bucking US decline, region's start-ups lure more moneyBoston Globe
Austin American-Statesman -Earthtimes (press release) -CBS 5
all 246 news articles »

To Read More: Venture Capital Investing Climbs to $4.73 Billion (Correct) – BusinessWeek
categoriaUncategorized commentoComments Off on Venture Capital Investing Climbs to $4.73 Billion (Correct) – BusinessWeek | dataApril 16th, 2010
Read All

Biotechnology’s benefits for US farmers – Western Farm Press

By Dr. Matthew Watson


FinFacts Ireland
Biotechnology's benefits for US farmers
Western Farm Press
"Decades of documented evidence demonstrate that agricultural biotechnology is a safe and beneficial technology that contributes to both environmental and ...
Mounting Evidence Shows Positive Impact of Biotech CropsWisconsin Ag Connection

all 6 news articles »

To Read More: Biotechnology’s benefits for US farmers – Western Farm Press
categoriaUncategorized commentoComments Off on Biotechnology’s benefits for US farmers – Western Farm Press | dataApril 16th, 2010
Read All

Whitworth elected to Genzyme’s board – Boston Globe

By Dr. Matthew Watson


The Money Times
Whitworth elected to Genzyme's board
Boston Globe
Genzyme Corp., the large Cambridge biotechnology company, said that that Ralph Whitworth, principal and co-founder of Relational Investors LLC, ...
Genzyme moves to strengthen defenses against IcahnReuters
Genzyme adds Whitworth to block IcahnPharma Times
Ralph Whitworth Elected to Genzyme's Board of DirectorsMarketWatch (press release)
Boston Herald -Boston Business Journal -Xconomy
all 61 news articles »

To Read More: Whitworth elected to Genzyme’s board – Boston Globe
categoriaUncategorized commentoComments Off on Whitworth elected to Genzyme’s board – Boston Globe | dataApril 16th, 2010
Read All

MSU student receives Barry M. Goldwater Scholarship – MSU State News

By Dr. Matthew Watson


MSU State News
MSU student receives Barry M. Goldwater Scholarship
MSU State News
When Tasneem Pierce sat down with an assistant professor about a possible major change, the genomics and molecular genetics junior quickly decided what ...

and more »

To Read More: MSU student receives Barry M. Goldwater Scholarship – MSU State News
categoriaUncategorized commentoComments Off on MSU student receives Barry M. Goldwater Scholarship – MSU State News | dataApril 16th, 2010
Read All

Bucking US decline, region’s start-ups lure more money – Boston Globe

By Dr. Matthew Watson


VentureBeat
Bucking US decline, region's start-ups lure more money
Boston Globe
Still, 2010 is off to a better start than 2009, as biotechnology and medical devices continued to lead other industries in both number of deals and money ...
Venture funding rebounds for Austin startupsAustin American-Statesman
Summary Box: Venture-Cap Investments Rise In 1QCBS 5
Venture-cap investments rise in 1Q, as optimism upThe Associated Press
Bizjournals.com -techrockies.com
all 127 news articles »

To Read More: Bucking US decline, region’s start-ups lure more money – Boston Globe
categoriaUncategorized commentoComments Off on Bucking US decline, region’s start-ups lure more money – Boston Globe | dataApril 16th, 2010
Read All

Weak Kidneys Cause Weak Bones

By Dr. Matthew Watson

by Jean-Claude Alix, Naturopath

No single area of the body stands alone, everything is linked up. This is why medical specialisation is one of the greatest mistakes that was ever

made.

Viewed from this angle, hardly any two areas are so closely and deeply intertwined as the renal metabolism and the bone metabolism. Thus, it is understandable that weakness in the kidneys must necessarily result in weakness in the bones. The discussion of these interrelations is the

theme of this treatise.

Significance of the kidney as the centre of bone formation:

- The kidney as regulator of the

electrolytes

- The kidney as regulator of the

acid-alkaline balance

- The kidney as the base of anxiety Read more...

Joint Mender for Joint Care

To Read More: Weak Kidneys Cause Weak Bones
categoriaIntegrative Medicine commentoComments Off on Weak Kidneys Cause Weak Bones | dataApril 15th, 2010
Read All

3-Parent Embryos Could Prevent Disease, But Raise Ethical Issues – Wired News

By Dr. Matthew Watson


Reuters
3-Parent Embryos Could Prevent Disease, But Raise Ethical Issues
Wired News
The technique is a subtle form of genetic engineering, which many people consider taboo, and raises other ethical dilemmas. It could also allow parents ...
Three-Parent Babies Due Soon, Thanks to ScienceFOXNews

all 145 news articles »

To Read More: 3-Parent Embryos Could Prevent Disease, But Raise Ethical Issues – Wired News
categoriaUncategorized commentoComments Off on 3-Parent Embryos Could Prevent Disease, But Raise Ethical Issues – Wired News | dataApril 15th, 2010
Read All

CORRECTED: Are regulators dropping the ball on biocrops? – Reuters

By Dr. Matthew Watson


Reuters
CORRECTED: Are regulators dropping the ball on biocrops?
Reuters
"One of the things that we think is important to do is to have regular reviews and updates of our strategies for regulating products of biotechnology," said ...
Are US regulators dropping the ball when it comes to biocrops?BusinessWorld Online
SPECIAL REPORT-Are US regulators dropping the ball on biocrops?Forexyard

all 18 news articles »

To Read More: CORRECTED: Are regulators dropping the ball on biocrops? – Reuters
categoriaUncategorized commentoComments Off on CORRECTED: Are regulators dropping the ball on biocrops? – Reuters | dataApril 15th, 2010
Read All

F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent

By Dr. Matthew Watson

Plans by  FDA to Adopt stricter standards for Bioequivalence, Bioavailability for generic drugs could sound trouble for Indian Generic Manufactures. Already most of the smaller companies are finding it difficult to get FDA approval letters. QSR Draft Guidance An industry working group has urged the FDA to consider adopting its guidance to outline quality system requirements (QSR) for bioequivalence and bioavailability testing during drug clinical trials.

There was a recent report in NY times that mentioned about several thousand patients receiving nitroglycerin tablets that were not approved by FDA http://www.nytimes.com/2010/03/27/business/27nitro.html

FDA recently evaluated 2070 human studies conducted between 1996 and 2007. These studies compared the absorption of brand name and generic drugs into a person’s body. These studies were submitted to FDA to support approval of generics. The average difference in absorption into the body between the generic and the brand name was only 2.3%. Some generics were absorbed slightly more, some slightly less. This amount of difference would be expected and acceptable, whether for one batch of brand name drug tested against another batch of the same brand, or for a generic tested against a brand name. In fact, there have been studies in which branded drugs were compared with themselves, as well as with a generic. As a rule, the difference for the generic-to-brand comparison was about the same as the brandto- brand comparison” (www.fda.gov/ Drugs/ResourcesForYou/Consumers/ BuyingUsingMedicineSafely/Under standingGenericDrugs/ucm167991. htm)

Fore more updates attend the event below

Attend the http://www.informaglobalevents.com/event/beba

To Read More: F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent
categoriaUncategorized commentoComments Off on F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent | dataApril 15th, 2010
Read All

East Africa: South Africa Leads in GM Crops as EA Lags Behind – AllAfrica.com

By Dr. Matthew Watson


Reuters
East Africa: South Africa Leads in GM Crops as EA Lags Behind
AllAfrica.com
With reduced requirements for farm inputs and increased yields per unit area, genetic engineering, a modern form of biotechnology, could transform the ...
Green thumbsTruth about Trade & Technology
Weeds improve resistance to RoundupSt. Louis Post-Dispatch
Some weeds, bugs grew resistant to genetically engineered cropsUSA Today
Environment News Service -Treehugger -DesMoinesRegister.com
all 59 news articles »

To Read More: East Africa: South Africa Leads in GM Crops as EA Lags Behind – AllAfrica.com
categoriaUncategorized commentoComments Off on East Africa: South Africa Leads in GM Crops as EA Lags Behind – AllAfrica.com | dataApril 14th, 2010
Read All

US Reps propose tougher Medicare fraud penalties – WZVN-TV

By Dr. Matthew Watson


Journal Record (subscription)
US Reps propose tougher Medicare fraud penalties
WZVN-TV
The proposed bill would double prison sentences for Medicare fraud and use biotechnology such as fingerprint scanning to ensure patients are getting the ...
House bill would double Medicare fraud penaltiesJournal Record (subscription)

all 23 news articles »

To Read More: US Reps propose tougher Medicare fraud penalties – WZVN-TV
categoriaUncategorized commentoComments Off on US Reps propose tougher Medicare fraud penalties – WZVN-TV | dataApril 14th, 2010
Read All

International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells

By Dr. Matthew Watson

International Stem Cell Corporation (OTCBB:ISCO), http://www.intlstemcell.com, today added two world-leading immunogeneticists to its scientific advisory board. They and ISCO scientists will study the immune-matching properties of ISCO's human parthenogenetic stem cell (hpSC) technology and the potential for each hpSC-derived therapeutic cell to be an immune-match for millions of people.

Dr. Hans-Dieter Volk, Professor of Immunology and Chair of the Institute of Medical Immunology and Berlin-Brandenburg Center for Regenerative Therapies (BCRT) at Charité Universitätsmedizin in Berlin, and Dr. Matthias von Herrath, Professor at the La Jolla Institute of Allergy and Immunology at University of San Diego, have agreed to join ISCO's scientific advisory board. Both have dedicated their careers to experimental and clinical immunology and are highly regarded immunogenetics experts internationally. They will be most valuable as ISCO attempts to demonstrate the unique immune-matching benefits of the hpSC technology experimentally and in clinical practice.

"We believe that providing human cells that can minimize rejection though immune-matching to the recipient is one of the most important tasks in developing effective regenerative medicine therapies," says Dr. Simon Craw, Vice President at ISCO. "We look forward to Drs. Volk and von Herrath helping us try to demonstrate how that need can be met with our parthenogenetic stem cells."

Embryonic stem cells (hESC) almost invariably have different forms of genes (called "alleles") at each genetic position of the paternal and maternal chromosomes, i.e. they are "heterozygous." This includes the human leukocyte antigen ("HLA") genes that are largely responsible for the distinction between "self" and "foreign," and thus acceptance or rejection of transplants. Since hESC are derived from fertilized embryos, they carry the genes of a unique individual, thus the therapeutic cells derived from hESC will carry HLA alleles that can be recognized as foreign and be rejected by most patients unless they receive immunosuppressive therapy. Such therapy is costly, has significant side effects, and often is disabling in the long term.

Like most individuals in the population, induced pluripotent stem cells ("iPS" cells) and adult stem cells are also predominantly heterozygous because they carry paternal and maternal chromosomes. They are a perfect immune match to the patient they came from and are therefore typically administered back to that same individual ("autologous therapy"). However, they would likely be rejected by most other recipients. Autologous therapy is time-consuming and expensive, which goes against the cost containment pressures globally. In addition, the quality of the therapy is directly related to the ability to secure clinically sufficient numbers of functional cells from the patient, which often poses a significant problem in clinical practice.

In contrast, the hpSCs developed by ISCO are derived from unfertilized eggs ("oocytes") that have been shown in peer-reviewed journals to exhibit unlimited proliferation potential and are pluripotent (can become cells from all three germ layers that form a human being). Most significantly, hpSC can be created in a "homozygous" state, where the alleles, including the HLA alleles, are the same at each genetic position. When these HLA alleles are also found with a high frequency in a population, these "HLA-homozygous" stem cells and their therapeutic derivatives have the potential to be immune matched to millions of people. For example, ISCO's first homozygous stem cell line with high-frequency HLA alleles has the potential to be immune matched to an estimated 75 million people worldwide.

Dr. Volk says: "Using my experience from transplantation immunology and medicine during the past three decades, I am very pleased to help ISCO in their efforts to make its hpSC technology a clinical reality where therapeutic cell derivatives will be immune matches for millions of people worldwide." Dr. von Herrath continues: "While stem cell technologies generally offer great regenerative potential, most clinical applications will be limited by immune rejection. I look much forward to joining ISCO in their quest for making stem cell-derived therapy a practical and attractive clinical option for many degenerative diseases."

Besides the immunogenetic developments, ISCO is advancing its hpSC technology into the differentiation of hpSC into therapeutic cells and tissues and into the establishment of processes and facilities to produce clinical-grade cells. The company is seeking to demonstrate the therapeutic potential of its hpSC technology as a safe, efficient, and superior alternative to other sources of stem cells for human therapy.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology. More information is available at ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated technological developments and therapeutic applications, and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Brian Lundstrom, President
760-640-6383
bl@intlstemcell.com

To Read More: International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells
categoriaStem Cell Therapy commentoComments Off on International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells | dataApril 14th, 2010
Read All

Law Headlines:Is it fair to patent genes? ACLU takes on biotech over issue – Legal Info Today

By Dr. Matthew Watson


TopNews United States
Law Headlines:Is it fair to patent genes? ACLU takes on biotech over issue
Legal Info Today
A successful ACLU lawsuit against the biotechnology company Myriad Genetics over the BRCA gene has some celebrating and others alarmed. ...
The profit strandThe Age
Making sense of patentsABC Online
Is it fair to patent genes? ACLU takes on biotech over issueUSA Today
Bizmology -Los Angeles Times -American Medical News
all 20 news articles »

To Read More: Law Headlines:Is it fair to patent genes? ACLU takes on biotech over issue – Legal Info Today
categoriaUncategorized commentoComments Off on Law Headlines:Is it fair to patent genes? ACLU takes on biotech over issue – Legal Info Today | dataApril 14th, 2010
Read All

Monoclonal Antibodies Promise New Chances For Ovarian Cancer Therapy: Research … – Pharmaceutical Business Review

By Dr. Matthew Watson


Live-PR.com (press release)
Monoclonal Antibodies Promise New Chances For Ovarian Cancer Therapy: Research ...
Pharmaceutical Business Review
According to a research conducted by a group of scientists in partnership with professor Michael Krainer, director of the molecular genetics working group, ...
New options for the treatment of ovarian cancerPharmacy Europe

all 62 news articles »

To Read More: Monoclonal Antibodies Promise New Chances For Ovarian Cancer Therapy: Research … – Pharmaceutical Business Review
categoriaUncategorized commentoComments Off on Monoclonal Antibodies Promise New Chances For Ovarian Cancer Therapy: Research … – Pharmaceutical Business Review | dataApril 14th, 2010
Read All

CSC news roundup 2010-04-11

By Dr. Matthew Watson

To Read More: CSC news roundup 2010-04-11
categoriaStem Cell Therapy commentoComments Off on CSC news roundup 2010-04-11 | dataApril 12th, 2010
Read All

Page 391«..1020..389390391392